Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders. This development marks a significant step in protecting the company’s innovative approach to treating these debilitating conditions. The full press release is available at https://nnw.fm/PVbbH.
Greenland Mines is a Nasdaq-listed company with two operating divisions: Mining, focused on exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of a previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The patent grant provides legal protection for the company's gene therapy technology, which could be crucial for attracting partners and investors. However, forward-looking statements in the release caution that actual results may differ materially due to risks and uncertainties, including those described in the company's SEC filings. For the latest news and updates regarding GRML, visit the company’s newsroom at https://ibn.fm/GRML.
